Unknown

Dataset Information

0

The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine.


ABSTRACT: BACKGROUND:Use of the antipsychotic drug olanzapine by patients with schizophrenia is associated with autonomic nervous system (ANS) dysfunction. It is presumed that there are interindividual differences in ANS dysfunction that correspond to pharmacogenetics. In this study, we investigated whether genetic polymorphisms in ABCB1, CYP1A2, and UGT1A4 are associated with this observed ANS dysfunction. METHODS:A total of 91 schizophrenia patients treated with olanzapine monotherapy participated in this study. A power spectral analysis of heart rate variability was used to assess ANS activity. The TaqMan system was used to genotype seven single nucleotide polymorphisms (SNPs) in CYP1A2 (rs2069514 and rs762551), UGT1A4 (rs2011425), and ABCB1 (rs1045642, rs1128503, rs2032582, rs2235048). RESULTS:Sympathetic nervous activity was significantly higher in individuals with the UGT1A4 rs2011425 G allele than in those with the UGT1A4 rs2011425 non-G allele (sympathetic activity, p?=?.001). Furthermore, sympathetic nervous activity was also significantly associated with UGT1A4 rs2011425 genotype as revealed by multiple regression analysis (sympathetic activity, p?=?.008). CONCLUSIONS:We suggest that the UGT1A4 rs2011425 polymorphism affects olanzapine tolerability because it is associated with the observed side effects of olanzapine in schizophrenia patients, namely sympathetic dysfunction.

SUBMITTER: Hattori S 

PROVIDER: S-EPMC7027321 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine.

Hattori Saki S   Suda Akira A   Miyauchi Masatoshi M   Shiraishi Yohko Y   Saeki Takashi T   Fukushima Tadashi T   Fujibayashi Mami M   Tsujita Natsuki N   Ishii Chie C   Ishii Norio N   Moritani Tosiho T   Saigusa Yusuke Y   Kishida Ikuko I  

BMC psychiatry 20200218 1


<h4>Background</h4>Use of the antipsychotic drug olanzapine by patients with schizophrenia is associated with autonomic nervous system (ANS) dysfunction. It is presumed that there are interindividual differences in ANS dysfunction that correspond to pharmacogenetics. In this study, we investigated whether genetic polymorphisms in ABCB1, CYP1A2, and UGT1A4 are associated with this observed ANS dysfunction.<h4>Methods</h4>A total of 91 schizophrenia patients treated with olanzapine monotherapy par  ...[more]

Similar Datasets

| S-EPMC6050702 | biostudies-literature
| S-EPMC8076312 | biostudies-literature
| S-EPMC4822441 | biostudies-literature
| S-EPMC3554723 | biostudies-literature
| S-EPMC5587196 | biostudies-literature
| S-EPMC5094069 | biostudies-literature
| S-EPMC7054439 | biostudies-literature
| S-EPMC9054179 | biostudies-literature
| S-EPMC2930351 | biostudies-literature
| S-EPMC8764397 | biostudies-literature